Dr. Glode is the medical oncology specialist for prostate and genitourinary (GU) cancers at Shaw Cancer Center. He was the principal investigator on the study leading to the approval of leuprolide, an injection used for treating prostate cancer. He was also principal investigator on the first nation-wide National Cancer Institute sponsored adjuvant treatment protocol for high risk prostate cancer patients following surgery (SWOG 9921). With a longstanding interest in GU oncology, Dr. Glode's laboratory interests included studies on a toxin-conjugate that appears capable of directly killing tumor cells aberrantly expressing the GnRH receptor and eliminating pituitary gonadotropes. He is currently PI on an SBIR grant developing drugs for treating bladder cancer with a startup company he helped found, Aurora Oncology.
Dr. Glode is a Fellow of the American Society of Clinical Oncology and the American College of Physicians, and Professor Emeritus at the University of Colorado. He has been a principle investigator on numerous basic science and clinical research grants and has been recognized by the American Association of Cancer Research for his efforts in organizing a course called "Molecular Biology for Clinical Oncologists." He is a scientific advisor to several pharmaceutical companies, and has been a member of an External Advisory Board for the Department of Defense Prostate Cancer Research Program and review boards at the NCI and ACS. He has published more than 150 scientific articles, book chapters and monographs. His blog for prostate cancer patients can be found at www.prost8blog.com.